Answers are grounded in this paper and cite their sources.
In otherwise healthy preterm infants, palivizumab treatment resulted in a significant reduction in wheezing days during the first year of life, even after the end of treatment. These findings implicate RSV infection as an important mechanism of recurrent wheeze during the first year of life in such infants. (Funded by Abbott Laboratories and by the Netherlands Organization for Health Research and Development; MAKI Controlled Clinical Trials number, ISRCTN73641710.).
No takes yet. Share an insight, caveat, or question.
Blanken et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: